Y-Mabs Therapeutics EBIT

Y-Mabs Therapeutics's ebit stands at $-27M as of June 2025. That compares with $-28M in the prior-year period — up 4.2% year over year. That is below the Healthcare sector average of $23B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Y-Mabs Therapeutics reported $-27M in EBIT versus $-28M a year earlier — a 4.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Y-Mabs Therapeutics sits lower the Healthcare benchmark ($23B) with a EBIT of $-27M. That is roughly 100.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-28M in the prior-year period — up 4.2% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Y-Mabs Therapeutics's EBIT evolved across reporting periods, while the comparison chart places YMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.